ValiRx PLC Shareholder Requisition Notice (0337F)

TIDMVAL

RNS Number : 0337F

ValiRx PLC

04 March 2020

ValiRx Plc

("ValiRx" or the "Company")

Shareholder Requisition Notice

London, UK, 4 March 2020: ValiRx Plc (AIM: VAL), a clinical stage biotechnology company, announces that it has received a letter from a group of shareholders (the "Letter") who hold in excess of 5% of the issued share capital of the Company, requiring that the Company convene, as soon as reasonably practicable, a general meeting, at which resolutions will be proposed to remove George Morris and Satu Vainikka as directors of the Company.

The Letter is a requisition under section 303 of the Companies Act 2006.

The Company is mindful that, pursuant to section 304 of the Companies Act 2006, the Company must post a notice convening a general meeting within 21 days from the date on which the requisition notice was received, and this general meeting must be held on a date not more than 28 days after the date of the notice to shareholders convening the general meeting.

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.

For more information, please contact:

 
 ValiRx plc                                  Tel: +44 (0) 20 3008 4416 
                                              www.valirx.com 
 Kevin Alexander, Non-executive Director     Tel: +44 (0) 20 3008 4416 
 Tarquin Edwards, Head of Communications.    Tel: +44 (0) 7879 458 
                                              364 
                                              tarquin.edwards@valirx.com 
 
 Cairn Financial Advisers LLP (Nominated     Tel: +44 (0) 20 7213 0880 
  Adviser) 
  Liam Murray / Jo Turner / Ludovico 
  Lazzaretti 
 
 Allenby Capital Limited (Joint Broker)      Tel: +44 (0) 20 3328 5656 
  Jeremy Porter / Alex Brearley (Corporate 
  Finance) 
  Kelly Gardiner (Equity Sales) 
 
 ETX Capital Limited (Joint Broker)          Tel: +44 (0) 20 7392 1568 
  Thomas Smith 
 Novum Securities Limited (Joint Broker)     Tel: +44 (0) 20 7399 9400 
  Colin Rowbury

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCJIMATMTTMBFM

(END) Dow Jones Newswires

March 04, 2020 10:28 ET (15:28 GMT)

Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2024 to May 2024